Storia in 3 fonti

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.

Raccontata da

fiercepharma.com

endpoints.news

pharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

pharmaceutical-technology.comStai leggendo1 mese fa

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline closes $92.5M Series B to advance male contraceptive NES/T to Phase III, targeting 2027 FDA approval. The funding demonstrates VC interest in complex-regulated biotech, signaling capital flows beyond software—relevant context for startup-ecosystem diversification.

originale

fiercepharma.com1 mese fa

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's…

Contraline raised $92.5M Series B to advance NES/T Gel, a first-in-class topical male contraceptive, into phase 3 trials starting 2027. The round signals VC appetite for consumer-driven healthcare in underserved categories, positioning potential telehealth distribution.

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Confronto fonti

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's…

Timeline cronologica

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology